CytoSorbents Corporation (CTSO) announced that it does not have any direct financial exposure to Silicon Valley Bank (SIVB) or Signature Bank (SBNY). CytoSorbents has diversified cash holdings in multiple financial institutions, both domestically and internationally. In the U.S., in cooperation with Bridge Bank, CytoSorbents currently holds the majority of its cash holdings at JP Morgan Chase (JPM) and a minority at Bridge Bank.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CTSO:
- CytoSorbents Comments on Bank Exposure and Diversified Cash Position
- CytoSorbents reports Q4 revenue $9.4M, consensus $8.72M
- CytoSorbents Reports Fourth Quarter and Full Year 2022 Results
- CytoSorbents announces new European guidelines that consider hemoadsorption
- New European “Guidelines for the Management of Severe Perioperative Bleeding” Consider Hemoadsorption for the First-Time